Reports Q4 revenue $730.3M, consensus $742.25M. "During the fourth quarter, we continued to make progress, working through the ongoing global supply chain challenges," said Norman Schwartz, Bio-Rad’s President, and Chief Executive Officer. "We also saw positive market response to new product introductions, setting the stage for 2023."
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on BIO:
- Bio-Rad and Element Biosciences announce partnership
- Cytek Biosciences partners with Bio-Rad to expand reagent portfolios
- Singular Genomics showcases G4 sequencing data with 11 genomics partners
- Early notable gainers among liquid option names on January 26th
- Early notable gainers among liquid option names on January 11th
